Resistance to high-maintenance dose of prasugrel treated by ticagrelor: A case report

Platelets

Volumn 24, Issue 3, 2013, Pages 239-241

  Xanthopoulou, Ioanna ^a   Stavrou, Eleana F ^b   Kassimis, George ^a   Goudas, Pavlos ^c   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

High on treatment platelet reactivity; Prasugrel; Ticagrelor

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; PRASUGREL; TICAGRELOR;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CASE REPORT; CELL ASSAY; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNCTION TEST KIT; GENOTYPE; HEMODIALYSIS; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; MAINTENANCE DRUG DOSE; PLATELET REACTIVITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ACCESS;

ADENOSINE; ADULT; DRUG RESISTANCE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y; RENAL DIALYSIS; THIOPHENES;

EID: 84875696882     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.682104     Document Type: Article

References (25)

1. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-1954.
2. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, et al. Prasugrel compared with high loading-and maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-2932. (Pubitemid 350291199)
3. Alexopoulos D, Plakomyti TE, Xanthopoulou I. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity. Int J Cardiol 2012;154:333-334.
4. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, Fourtounas C, Goumenos D. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 2011;9:2379-2385.
5. Polkinghorne K. The CARI guidelines. Pharmacological approaches to preventing vascular access failure. Nephrology (Carlton) 2008;13(Suppl. 2):S12-S16. (Pubitemid 352033048)
6. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933.
7. Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006;3:387-395. (Pubitemid 43978399)
8. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305:1097-1105.
9. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
10. Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011;162:733-739.
11. Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthelemy O, Henry P, Lim P, Beygui F, Collet JP, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010;103:213-223.
12. Neubauer H, Kaiser A, Busse B, Mugge A. Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation-a preliminary study. Thromb Res 2010;126: e389-e391.
13. Rehmel JLF, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-607.
14. Farid NA, Payne CD, Small DS, Winters KJ, Ernest 2nd CS, Brandt JT, Darstein C, Jakubowski JA, Salazar DE. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-741. (Pubitemid 46625113)
15. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996;8:S21-S25.
16. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486-501. (Pubitemid 44767878)
17. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710. (Pubitemid 350190847)
18. Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 2012;129(4):441-446.
19. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 2010;121:1188-1199.
20. Morgan KP, More RS, Chauhan A. The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. Cardiology 2011;119:88-89.
21. Alexopoulos D, Xanthopoulou I, Panagiotou A, Komninakis D, Germanos N, Goudas P, Koutroulia E, Fourtounas C. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. Am J Kidney Dis 2012;59:469-471.
22. Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Muller K, Bigalke B, Stellos K, May AE, Flather M, Gawaz M, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 2011;22: 627-633.
23. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, Caillard S, Campia U, Moulin B, Gachet C, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011;57:399-408.
24. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-1067.
25. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Copetti M, Graziano G, Tognoni G, Jardine M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012; 156:445-459.